Patient Empowerment Program: A Rare Disease Podcast cover art

Patient Empowerment Program: A Rare Disease Podcast

Patient Empowerment Program: A Rare Disease Podcast

By: n-Lorem Foundation (Dr. Stan Crooke Amy Williford Kim Butler Andrew Serrano Jon Magnuson and Kira Dineen)
Listen for free

This Season's Biggest Deal | $0.99/mo for 3 months + $20 Audible bonus

Auto-renews at $8.99/mo. after 3 months - terms apply.
Summary
Join the nano-rare disease community! Interviews features leading physicians, scientists, biotech experts, and patient advocates. Lessons teach core concepts about drugs. Our host Dr. Crooke has led the creation of antisense technology and his foundation, n-Lorem, is using this powerful technology to discover, develop, and provide personalized experimental antisense oligonucleotide medicines to nano-rare patients for free, for life.

n-Lorem is a non-profit organization established to apply the efficiency, versatility and specificity of antisense technology to charitably provide experimental antisense oligonucleotide (ASO) medicines to treat patients (less than 30 patients) that are the result of a single genetic defect unique to only one or very few individuals. The advantage of experimental ASO medicines is that they can be developed rapidly, inexpensively and are highly specific. n-Lorem was founded by Dr. Stan Crooke, who founded IONIS Pharmaceuticals in 1989 and, through his vision and leadership, established the company as the leader in RNA-targeted therapeutics.

The podcast is produced by n-Lorem Foundation and hosted by Dr. Stanley T. Crroke, who is the Founder, CEO and Chairman. Our videographer is Jon Magnuson. Our producers are Kira Dineen, Jon Magnuson, Kim Butler, and Amy Williford. To learn more about n-Lorem, visit nlorem.org. Contact us at podcast@nlorem.org.Copyright 2024-2027 n-Lorem Foundation
Biological Sciences Hygiene & Healthy Living Physical Illness & Disease Science
Episodes
  • One Step Closer to Treatment with Raena and Frank Vrtochnick
    Nov 18 2026

    The Vrtochnick family recalls the moment they were told that their son’s investigational new drug application (IND) received a “may proceed” authorization from the FDA, meaning that a green light has been signaled for Gunnar to receive his ASO medicine charitably created by n-Lorem. Gunnar, a pre-teen from Wisconsin, lives with KIF1A-Associated Neurological Disorder (KAND) which causes him difficulties with spasticity and motor function. With this authorization, he hopes to begin treatment in the coming months.

    Hear about Gunnar's diagnosis, what a treatment means for his family, the community impact of the colloquium, and more in this Patient Empowerment Program podcast episode.

    In this episode we discuss:

    1:30 - Involvement in Rescue 7 and it becoming a colloquium staple for families

    2:35 – Meet the Vrtochnick family

    3:00 – Community impact of the Colloquium and meeting others facing similar difficulties

    4:07 – Gunnar's symptoms and diagnosis

    5:30 – What an n-Lorem discovered, developed, and charitably provided ASO medicine means to their family

    7:48 – The moment they were told that their son's IND received a "May proceed" authorization from the FDA

    11:43 – Gunnar's interests and him learning the importance of giving back

    ---

    Links:

    2027 Colloquium Interest Form

    2026 Colloquium Recap

    Donate to n-Lorem

    Sponsors:

    ChemGenes

    GondolaBio

    Show More Show Less
    21 mins
  • Why n-Lorem Must Sometimes Say No
    Nov 4 2026

    We're addressing perhaps the most difficult decision n-Lorem has to make in our work, declining a patient application. Today, our acceptance rate is ~59%. These decisions are made with heavy hearts at n-Lorem, and we are aware of how heartbreaking the decision to decline an application may be for a patient and their family. In this episode, we'll discuss the main reasons a patient's application may be denied, including safety, geography, and other factors.

    On This Episode We Discuss:

    • 1:43 – Non-technical issues: Outside of USA, inability to find treating physician, patient population size, if the patient is being treated by another experimental medicine, including repurposed drugs
    • 7:15 – Definitions to better understand the conversation: Heterozygous mutation, haploinsufficiency
    • 9:40 – n-Lorem must understand the cause of the disease, the nature of the mutation, and n-Lorem must be confident that the ASO designed would deliver value to the patient
    • 12:35 – n-Lorem must be confident that only a single gene is causing phenotypes, and that the target is not a null mutation
    • 13:37 – n-Lorem may accept patients, but then discontinue a program if the patient cells are unable to be grown for lab use and testing
    • 14:56 – For patients requiring an allele-selective ASO, n-Lorem must identify non-pathogenic mutations to attempt to create an ASO capable of helping the patient

    Links:

    Donate - https://www.nlorem.org/donate/

    Sponsors:

    Hongene - https://www.hongene.com/

    GondolaBio - https://gondolabio.com/

    Show More Show Less
    19 mins
  • Sneak Peek of the 2026 Nano-rare Patient Colloquium
    Sep 10 2026

    A lot can happen in a year, and at n-Lorem, this past year has brought important milestones, new developments, and plenty to discuss at the upcoming 2026 Nano-rare Patient Colloquium.

    In this special Colloquium preview episode, Brady Huggett, editor-in-chief of Asimov Press and longtime moderator of the Colloquium’s patient experience panel, returns to sit down with n-Lorem CEO Stan Crooke. Together, they reflect on the past year, explore some of the topics likely to take center stage, and preview what attendees can expect at the 2026 Nano-rare Patient Colloquium.

    On this episode:

    2:28 – What is a day in the life of an n-Lorem research team member?

    9:08 – How many ASOs are required to move into tolerability studies and what may cause a program to be terminated

    12:05 – Improvements in efficiencies, bringing down costs, and growth have allowed n-Lorem to respond to the extraordinary demand

    13:14 – Discussing the creation of individualized ASOs for two boys with SCN2A mutations and their potential to help others with the same mutation and single nucleotide variant

    25:00 – Thoughts on the FDA’s Plausible Mechanism Framework

    29:00 – Commercial opportunities will not alter the n-Lorem charitable arm but will provide sustainable revenues to charitably treat more patients

    36:05 – What are the Limits of Hope and expanding those limits

    37:54 – Empathy is an expanded sense of self, and a sphere of oneness is felt at the Colloquium

    Links:

    2026 Nano-rare Patient Colloquium

    Donate to n-Lorem

    Episode and NRPC Gold Sponsors:

    ChemGenes

    GondolaBio

    Hongene Biotech

    Show More Show Less
    47 mins
No reviews yet
In the spirit of reconciliation, Audible acknowledges the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respect to their elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today.